Divestiture

KNOREX pitches its AscendX carve-out as a strategic AI pivot, but a forensic look at SEC filings reveals a desperate bid to save a depleted balance sheet.

Facing a massive 2027 debt wall, EyeCare Partners is selling its optometry arm. The move signals the collapse of the unified eye care consolidation model.

MyEyeDr.'s acquisition of 300 optometry clinics from EyeCare Partners reveals the quiet, debt-driven unraveling of private equity's vision care mega-platforms.

As the water sector faces a severe workforce retirement cliff, WEF liquidates its physical headquarters to inject $1 million into frontline member associations.

UPG Enterprises has filed for Chapter 11 bankruptcy, triggering an aggressive 60-day sale of its U.S. steel assets while shielding its EV and global divisions.

Shell’s sale of the Na Kika and Coulomb fields reveals the complex financial and environmental choreography of aging offshore infrastructure.

Fannie Mae just sold $203M in non-performing loans above par. Susan Powell explores how massive home equity cushions are flipping the distressed debt market.

Titan International’s $285 million divestiture of ITM isn’t just a balance sheet cleanup—it’s a calculated pivot toward defense contracts and domestic manufacturing supremacy.

Vyne's sale of its medical division to MRO isn't just a corporate carveout—it's a calculated bet that pure-play technology can cure dental administrative burnout.

Axe Compute sells its Helomics cancer lab, completing its pivot to a pure-play AI infrastructure provider and betting its future on the GPU gold rush.

As AdaptHealth hits the investor circuit, it faces tough questions on profitability, strategy shifts, and recent setbacks. Can leadership reassure the market?

Sauer Brands is divesting its spice business to focus on Duke's Mayo, while heritage brand Watkins expands its 150-year-old flavor empire.

Formerly Bit Origin, SANGRIX is cashing in its crypto holdings to chase the AI boom. But can a small Dogecoin sale fund a move into a capital-intensive industry?

As Holley courts investors, it's shedding assets to focus on core performance. Can this leaner strategy win over Wall Street amid industry crosswinds?

As advanced therapies reshape medicine, the race to control their complex supply chains heats up. Resonant's latest acquisition places it at the heart of Europe's booming market.

MatrixCare goes independent via a Frazier Healthcare acquisition, appointing a new CEO to accelerate innovation in the critical post-acute care tech space.

TPM's sale of ColorLab to its VP marks a strategic split. As TPM chases an AI-driven future, ColorLab gains independence to grow its branding legacy.

A NASDAQ-listed shipping firm scuttles its entire fleet to become a digital asset powerhouse. SVRN's all-in bet on NEAR Protocol is a bold reinvention.

With no revenue and a legacy business sold off, DNA X is betting its future on an AI trading platform. A deep dive into the numbers reveals a high-wire act.

Quimbaya Gold sells a non-core asset in a savvy, non-dilutive deal to fund its flagship Tahami project, signaling a sharp focus on high-potential targets.